Biotech Values

[jessellivermore]

Dear Gary,

Do you think today is the final chapter in DNDN?

I have been aware of this company for several years. Never have I considered buying any shares. The stockmarket can stay irrational longer than you can solvent. DNDN is merely the latest in a long line of companies whose PPS is not based very firml;y on reality.

DNDN kind of reminds me of Genzyme Tissue Repair..It was a gadget stock where doctors were suppose to harvest cartiledge, shipping it to the company who would grow it in tissue culture, later to returnit to the clinician who would use the regenerated cartiledge in injured knees. TR ran from three and an eighth to 28 and one half...before returning to earth and eventually closing up.

Provenge clinical effect is fairly marginal, and by reports they expect to get a lot per treatment....The insurance industry and the government are probably not going to roll over for this....